V. Campbell

发表

Cyclin and Cyclin-Dependent Kinase Substrate Requirements for Preventing Rereplication Reveal the Need for Concomitant Activation and Inhibition

F. Cross, V. Archambault, A. Ikui, 2007, Genetics.

Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma

B. Alman, B. Dickson, J. Wunder, 2014, Cancer.

Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity

J. Kutok, M. Read, J. Proctor, 2014, PloS one.

and substrate requirements for preventing re-replication reveal the need for concomitant activation and inhibition

V. Archambault, A. Ikui, B. Drapkin, 2006 .

KYM‐001, A FIRST‐IN‐CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88‐MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION

S. Rusin, D. Vigil, A. Mcdonald, 2019, Hematological Oncology.

Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth

B. Alman, J. Wunder, Lauren W. Wang, 2014, Molecular Cancer Therapeutics.

The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines

J. Kutok, H. Stern, J. Proctor, 2013 .

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

Jeanne A. Ferguson, J. Sydor, J. Adams, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Abstract LB-380: Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926

B. Alman, J. Wunder, H. Whetstone, 2011 .

Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders

R. Birge, D. Vigil, K. Sharma, 2023, Frontiers in immunology.

Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth

B. Alman, J. Wunder, Lauren W. Wang, 2014, Molecular Cancer Therapeutics.